3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
531
Squamous Cell Carcinoma of Head and Neck
273
Head and Neck Neoplasms
252
Lung Neoplasms
238
Uterine Cervical Neoplasms
176
Stomach Neoplasms
168
Esophageal Neoplasms
160
Nasopharyngeal Carcinoma
123
Urinary Bladder Neoplasms
116
Esophageal Squamous Cell Carcinoma
114
Neoplasms
113
Small Cell Lung Carcinoma
103
Breast Neoplasms
92
Ovarian Neoplasms
89
Neoplasm Metastasis
89
Carcinoma, Squamous Cell
76
Cholangiocarcinoma
75
Pancreatic Neoplasms
71
Biliary Tract Neoplasms
69
Mesothelioma, Malignant
57
Oropharyngeal Neoplasms
56
Carcinoma
55
Adenocarcinoma Of Esophagus
52
Recurrence
47
Parkinson Disease 4, Autosomal Dominant Lewy Body
47
Carcinoma, Ovarian Epithelial
45
Nasopharyngeal Neoplasms
41
Lymphoma
41
Adenocarcinoma of Lung
41
Gallbladder Neoplasms
38
Interventions
vandetanib
2
Thoracoscopy
2
Povidone-Iodine
2
Cisplatin
2
dalotuzumab
1
X-Rays
1
Ultrasonography
1
Tyrosine Kinase Inhibitors
1
Tissue Plasminogen Activator
1
Tenecteplase
1
Saline Solution
1
Receptors, Vascular Endothelial Growth Factor
1
Pleurodesis
1
Pemetrexed
1
Octreotide
1
Naproxen
1
Gemcitabine
1
Fentanyl
1
Diclofenac
1
Deoxyribonucleases
1
Dasatinib
1
Darbepoetin alfa
1
Clinical Laboratory Techniques
1
Chest Tubes
1
Cdc25C phosphatase (211-221)
1
Afatinib
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Pleural Effusion
×
Cisplatin
×
Clear all
NCT00942825
2017-05-24
CBP08-02
CanBas Co. Ltd.
Phase 2
Completed
195 enrolled
8 charts
NCT00799240
2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2
Completed
27 enrolled